Ariyasu Mari相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study.

在 1/2 期初免-加强研究中，对 SARS-CoV-2 重组疫苗 S-268019-b 的免疫反应进行纵向分析

期刊:Frontiers in Immunology

影响因子:5.9

doi:10.3389/fimmu.2025.1550279

Fujitani Masaya, Lu Xiuyuan, Shinnakasu Ryo, Inoue Takeshi, Kidani Yujiro, Seki Naomi M, Ishida Satoru, Mitsuki Shungo, Ishihara Takeshi, Aoki Miwa, Suzuki Akio, Takahashi Koji, Takayama Masahiro, Ota Takeshi, Iwata Satoshi, Shibata Risa Yokokawa, Sonoyama Takuhiro, Ariyasu Mari, Kitano Ayumi, Terooatea Tommy, Kelly Villa Jordan, Yamashita Kazuo, Yamasaki Sho, Kurosaki Tomohiro, Omoto Shinya

免疫/内分泌

发表日期：2025

文献求助收藏

Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study

在 PEDI-CEFI II 期研究中，对接受标准抗生素治疗的 3 个月至 18 岁以下住院感染患儿单剂量或多剂量头孢地洛的药代动力学、安全性和耐受性进行了评估。

期刊:Pediatric Infectious Disease Journal

影响因子:2.2

doi:10.1097/INF.0000000000004529

Bradley, John S; Orchiston, Elaine; Portsmouth, Simon; Ariyasu, Mari; Baba, Takamichi; Katsube, Takayuki; Makinde, Oluwaseun

发表日期：2025

文献求助收藏

A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults

一项在日本成年人中开展的COVID-19重组疫苗S-268019-b与ChAdOx1 nCoV-19疫苗的3期随机对照试验

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-024-57308-3

Iwata, Satoshi; Pollard, Andrew J; Tada, Yukio; Omoto, Shinya; Shibata, Risa Y; Igarashi, Kenji; Hasegawa, Takahiro; Ariyasu, Mari; Sonoyama, Takuhiro

发表日期：2024

文献求助收藏

Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults

一项针对啮齿动物的临床前研究以及一项针对日本成年人的 COVID-19 疫苗 S-268019-a 的 1/2 期随机、双盲、安慰剂对照、平行组研究的结果

doi:10.1016/j.vaccine.2022.12.025

Sonoyama, Takuhiro; Iwata, Satoshi; Shinkai, Masaharu; Iwata-Yoshikawa, Naoko; Shiwa-Sudo, Nozomi; Hemmi, Takuya; Ainai, Akira; Nagata, Noriyo; Matsunaga, Nobuaki; Tada, Yukio; Homma, Tomoyuki; Omoto, Shinya; Yokokawa Shibata, Risa; Igarashi, Kenji; Suzuki, Tadaki; Hasegawa, Hideki; Ariyasu, Mari

发表日期：2023

文献求助收藏

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings

日本受试者新冠疫苗1/2期临床试验：中期结果报告

doi:10.1016/j.vaccine.2022.04.054

Iwata, Satoshi; Sonoyama, Takuhiro; Kamitani, Akari; Shibata, Risa; Homma, Tomoyuki; Omoto, Shinya; Igarashi, Kenji; Ariyasu, Mari

发表日期：2022

文献求助收藏

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

同情用头孢地洛作为辅助治疗治疗由极耐药铜绿假单胞菌引起的原生主动脉瓣心内膜炎

期刊:Clinical Infectious Diseases

影响因子:7.3

doi:10.1093/cid/ciy963

Edgeworth, Jonathan D; Merante, Domenico; Patel, Sanjay; Young, Christopher; Jones, Paul; Vithlani, Seema; Wyncoll, Duncan; Roberts, Peter; Jones, Andrew; Den Nagata, Tsutae; Ariyasu, Mari; Livermore, David M; Beale, Richard

发表日期：2019

文献求助收藏

Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance

针对病原体的临床开发旨在满足未满足的医疗需求：头孢地洛靶向碳青霉烯耐药性

期刊:Clinical Infectious Diseases

影响因子:7.3

doi:10.1093/cid/ciz829

Echols, Roger; Ariyasu, Mari; Nagata, Tsutae Den

发表日期：2019

文献求助收藏

Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study

针对耐碳青霉烯类革兰氏阴性病原体所代表的未满足的重大医疗需求，设计一项以病原体为中心的临床研究——国际多中心随机开放标签3期CREDIBLE-CR研究

期刊:Infection and Drug Resistance

影响因子:2.9

doi:10.2147/IDR.S225553

Bassetti, Matteo; Ariyasu, Mari; Binkowitz, Bruce; Nagata, Tsutae Den; Echols, Roger M; Matsunaga, Yuko; Toyoizumi, Kiichiro; Doi, Yohei

发表日期：2019

文献求助收藏